Highlights of the symposium: Prolonged survival in pulmonary hypertension and in myocardial infarction with adrenomedullin, improved glucose control in diabetes with amylin, and beneficial responses in acute migraine to a calcitonin gene-related peptide antagonist

Telcagepant (MK0974) is one of several calcitonin-gene-related peptide antagonists in development as a potential treatment for acute migraine attacks and is the first orally available drug in this class. Preclinical and clinical data are reviewed, which support the efficacy and tolerability of telcagepant for the treatment of migraine, particularly for patients unable to tolerate, or who have cardiovascular contraindications to, triptans.

Download Full-text

A Short on Ubrogepant

Journal of Pharmaceutical Research International ◽

10.9734/jpri/2021/v33i56a33888 ◽

2021 ◽

pp. 79-81

Author(s):

S. Padmaja ◽

J. Mohan

Keyword(s):

Receptor Antagonist ◽

Research Process ◽

Calcitonin Gene Related Peptide ◽

Review Article ◽

Acute Migraine ◽

Cgrp Receptor ◽

Related Peptide ◽

Calcitonin Gene ◽

Acute Attacks ◽

Cgrp Receptor Antagonist

Migraine is a mysterious disorder characterized by pulsating head ache, which is actually characterized to one side and comes in attacks which will be lasting for about 3-48 hours and can be associated with nausea,vomiting,sensitivity to sound,flashes of light,vertigoand diarrhoea [1]. Most of the drugs which are in current use for actue migraine like triptans, treats the disorder symptomatically. A novel group of drugs has been in research for the migraine which treats the disorder pathologically. Calcitonin gene – related peptide (CGRP) has a major role in the pathophysiology of the disorder and hence CGRP receptor antagonist, known as Gepants are in the research process [2]. Gepants are being studied for the efficacy of treating acute migraine [2]. This article will be a review article about the drug – Ubrogepant, which is approved for treatment of migraine with acute attacks in adults [3].

Download Full-text

Effect of Calcitonin Gene-Related Peptide Receptor Antagonists on Migraine Treatment: A Meta-Analysis

10.21203/rs.3.rs-603934/v1 ◽

2021 ◽

Author(s):

Jiyoung Kim ◽

Kyoungjune Pak ◽

Gha-Hyun Lee ◽

Jae Wook Cho ◽

Hyun-Woo kim

Keyword(s):

Meta Analysis ◽

Calcitonin Gene Related Peptide ◽

Migraine Treatment ◽

Acute Migraine ◽

Cgrp Receptor ◽

Receptor Antagonists ◽

Related Peptide ◽

Calcitonin Gene ◽

Cgrp Receptor Antagonists ◽

Acute Migraine Treatment

Abstract Background: The pathophysiology of migraine has been researched incessantly, and it has been suggested that calcitonin gene-related peptide (CGRP) is associated with migraine attacks. CGRP receptor blockers are attracting attention for migraine prevention and treatment of acute episodes, and CGRP receptor antagonists have been shown to be effective in treating acute migraine headaches. This meta-analysis aimed to assess the effect of available CGRP receptor antagonists, focusing on their therapeutic doses for acute migraine treatment.Methods: We performed a systematic search of MEDLINE (from inception to March 2021) and EMBASE (from inception to March 2021) for English publications using the keywords “migraine” and “Calcitonin gene-related peptide,” limited to human studies.Results: Five studies that focused on examining the effects of CGRP receptor antagonists on acute migraine treatment met the eligibility criteria for this meta-analysis. The pooled analysis demonstrated that the CGRP receptor antagonist improved freedom from pain (OR=2.066, 95% confidence interval [CI] 1.766–2.418, I2=0%), absence of bothersome symptoms (OR=1.606, 95% CI=1.408–1.830, I2=0%), pain relief (OR=1.791, 95% CI=1.598–2.008, I2=0%), and freedom from nausea (OR=1.361, 95% CI=1.196–1.548, I2=0%), significantly more than the placebo. Conclusions: CGRP receptor antagonists are effective for acute migraine treatment and are expected to be used clinically as emerging therapeutic agents.

Download Full-text

Rimegepant: first novel oral calcitonin gene-related peptide inhibitor for migraine

International Journal of Basic & Clinical Pharmacology ◽

10.18203/2319-2003.ijbcp20201768 ◽

2020 ◽

Vol 9 (5) ◽

pp. 829

Author(s):

Saravana Kumar Ramasubbu ◽

Senkadhirdasan Dakshinamurthy ◽

Sarika Palepu ◽

Arkapal Bandyopadhyay ◽

Sathish Kumar Rajendran

Keyword(s):

Area Under The Curve ◽

Cardiovascular Effects ◽

Calcitonin Gene Related Peptide ◽

Causative Role ◽

Acute Migraine ◽

Related Peptide ◽

Calcitonin Gene ◽

Effective Option ◽

Inflammatory Drugs ◽

Cgrp Antagonist

Migraine is a neurological condition characterized by intense, debilitating headaches. Symptoms may include nausea, vomiting, numbness or tingling, sensitivity to light and sound. There are multitude of drugs available to treat migraine like triptans, non-steroidal anti-inflammatory drugs, ergots and opioids. But these drugs are associated with adverse effects especially triptans causing cardiovascular effects limiting its use. During last decade, calcitonin gene-related peptide (CGRP) has emerged as a possible mechanism for management of migraine. CGRP has been shown to release during episode of migraine attack and it may play a causative role in induction of migraine. Rimegepant is a novel CGRP antagonist has been approved by FDA for treatment of acute migraine. Rimegepant is a first oral CGRP antagonist compared to other gepants. The oral bioavailability of Rimegepant is 64% and high fat meal can decrease the Cmax, Tmax and area under the curve. This drug is mainly metabolized by CYP3A4 and to lesser extent by CYP2C9. Most common adverse reactions associated with this drug were nausea and urinary tract infection. Clinical trials for Rimegepant have been positive, and results suggest that the drug may be a new safe and effective option for treatment of acute migraine.

Download Full-text